Trial record 1 of 5 for:    certolizumab pegol and psoriatic arthritis
Previous Study | Return to List | Next Study

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB BIOSCIENCES GmbH )
ClinicalTrials.gov Identifier:
NCT01087788
First received: March 15, 2010
Last updated: July 31, 2014
Last verified: July 2014

March 15, 2010
July 31, 2014
March 2010
November 2011   (final data collection date for primary outcome measure)
  • American College of Rheumatology 20 (ACR20) Response at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
    ACR20 responders are those subjects with at least 20 % improvement from Baseline for Tender Joint Count (TJC), Swollen Joint Count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS).
  • Change From Baseline in Modified Total Sharp Score (mTSS) in Modification for Psoriatic Arthritis at Week 24 [ Time Frame: From Baseline to Week 24 ] [ Designated as safety issue: No ]

    Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 64 and 52 joints, respectively, with higher scores representing greater damage. mTSS (bone erosions) ranges from 0 (best possible outcome) to 320 (worst possible outcome); mTSS (joint space narrowing) ranges from 0 (best possible outcome) to 208 (worst possible outcome); and total score ranges from 0 (best possible outcome) to 528 (worst possible outcome).

    For the pre-defined analysis of this outcome measure, 0 was used for Baseline and the maximum observed mTSS value was used for Week 24 for those subjects which had less than 2 radiographs.

    The re-analysis is restricted to those subjects in the Randomized Set who have at least 2 x-ray values at scheduled visits, which are at least 8 weeks apart.

  • American College of Rheumatology 20 (ACR20) response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • modified Total Sharp Score (mTSS) change from baseline [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01087788 on ClinicalTrials.gov Archive Site
  • American College of Rheumatology 20 (ACR20) Response at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    ACR20 responders are those subjects with at least 20 % improvement from Baseline for Tender Joint Count (TJC), Swollen Joint Count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog Scale (PhGADA-VAS).
  • Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 24 [ Time Frame: From Baseline to Week 24 ] [ Designated as safety issue: No ]
    The HAQ-DI is a measure of function in Arthritis. There are 20 items in eight categories that represent a comprehensive set of functional activities on a scale from 0 (without difficulty) to 3 (unable to perform without assistance). The category scores are averaged into an overall HAQ-DI from 0 to 3. Scores of 0 to 1 generally represent mild to moderate difficulty, 1 to 2 represent moderate to severe disability, and 2 to 3 indicate severe to very severe disability. A negative value in HAQ-DI change from Baseline indicates an improvement from Baseline. The higher the negative value, the higher the improvement.
  • Psoriasis Area Severity Index (PASI75) Response at Week 24 in the Subgroup of Subjects With Psoriasis (PSO) Involving at Least 3 % Body Surface Area (BSA) at Baseline [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
    The PASI75 response assessments are based on at least 75 % improvement in the PASI score from Baseline. The PASI score is a measure of the average redness, thickness, and scaliness of the psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement.
  • Change From Baseline in Modified Total Sharp Score (mTSS) at Week 48 [ Time Frame: From Baseline to Week 48 ] [ Designated as safety issue: No ]

    Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 64 and 52 joints, respectively, with higher scores representing greater damage. mTSS (bone erosions) ranges from 0 (best possible outcome) to 320 (worst possible outcome); mTSS (joint space narrowing) ranges from 0 (best possible outcome) to 208 (worst possible outcome); and total score ranges from 0 (best possible outcome) to 528 (worst possible outcome).

    For the analysis of this outcome measure, the change from Baseline to Week 48 was imputed using the median change from Baseline among all subjects for those subjects, which had less than 2 radiographs.

    The post-hoc analysis presented here is based on the subgroup of subjects which had a Baseline mTSS value greater than 6.

  • American College of Rheumatology 20 (ACR20) response [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Health Assessment Questionnaire - Disability Index (HAQ-DI) change from baseline [ Time Frame: Week 12, Week 24, Week 48 ] [ Designated as safety issue: No ]
  • modified Total Sharp Score (mTSS) change from baseline [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
  • Psoriasis Area Severity Index (PASI75) response in the subgroup of subjects with Psoriasis (PSO) involving at least 3% Body Surface Area (BSA) at Baseline [ Time Frame: Week 12, Week 24 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult-Onset Active and Progressive Psoriatic Arthritis (PsA)

Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in subjects with adult onset active and progressive Psoriatic Arthritis (PsA).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Arthritis, Psoriatic
  • Biological: CZP 200 mg Q2W
    200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
    Other Names:
    • Cimzia
    • Certolizumab Pegol
  • Biological: CZP 400 mg Q4W
    400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
    Other Names:
    • Cimzia
    • Certolizumab Pegol
  • Other: Placebo
    Matching Placebo to CZP injection.
  • Experimental: CZP 200 mg Q2W

    Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.

    At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.

    Interventions:
    • Biological: CZP 200 mg Q2W
    • Other: Placebo
  • Experimental: CZP 400 mg Q4W

    Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.

    Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind.

    Interventions:
    • Biological: CZP 400 mg Q4W
    • Other: Placebo
  • Placebo Comparator: Placebo

    Matching Placebo to Certolizumab Pegol (CZP) injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group and were re-randomized to either CZP 200 mg Q2W or CZP 400 mg Q4W arm on Week 16.

    After 24 weeks, all subjects were re-randomized to active treatment with CZP 200 mg every two weeks (Q2W) or CZP 400 mg every four weeks (Q4W).

    Intervention: Other: Placebo
  • Placebo to CZP 200 mg escape on Week 16
    Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
    Interventions:
    • Biological: CZP 200 mg Q2W
    • Other: Placebo
  • Placebo to CZP 400 mg escape on Week 16
    Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
    Interventions:
    • Biological: CZP 400 mg Q4W
    • Other: Placebo
  • Placebo to CZP 200 mg on Week 24
    Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
    Interventions:
    • Biological: CZP 200 mg Q2W
    • Other: Placebo
  • Placebo to CZP 400 mg on Week 24
    Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
    Interventions:
    • Biological: CZP 400 mg Q4W
    • Other: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
409
August 2015
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of adult-onset Psoriatic Arthritis (PsA) of at least 6 months' duration as defined by the Classification Criteria for Psoriatic Arthritis (CASPAR criteria)
  • Active Psoriatic Skin Lesions or a documented history of Psoriasis
  • Active Arthritis with ≥ 3 tender joints at Screening and Baseline, ≥ 3 swollen joints at Screening and Baseline and fulfilling at least 1 of the following 2 criteria during the Screening Period:

    1. Erythrocyte Sedimentation Rate (ESR) (Westergren) ≥ 28 mm/hour
    2. C-reactive protein (CRP) > Upper Limit Normal (ULN)
  • Failure to 1 or more treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Exclusion Criteria:

  • Diagnosis of any other inflammatory Arthritis or known diagnosis of Fibromyalgia
  • Exposure to more than 1 Tumor Necrosis Factor α (TNFα) antagonist or to more than 2 previous biological response modifiers for PsA or Psoriasis
  • Any non-biological systemic treatment of Psoriasis; phototherapy; topical agents
  • History of chronic or recurrent infections
  • High risk of infection
  • Live vaccination within the 8 weeks prior to Baseline
  • Concurrent malignancy or a history of malignancy
  • Class III or IV congestive Heart Failure - New York Heart Association (NYHA)
  • Demyelinating disease of the central nervous system
  • Clinically significant laboratory abnormalities
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Belgium,   Brazil,   Canada,   Czech Republic,   France,   Germany,   Hungary,   Ireland,   Italy,   Mexico,   Poland,   Spain,   United Kingdom
 
NCT01087788
PsA001, 2009-011720-59
No
UCB Pharma ( UCB BIOSCIENCES GmbH )
UCB BIOSCIENCES GmbH
Not Provided
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 UCB
UCB Pharma
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP